Protara Therapeutics (TARA) Return on Capital Employed (2014 - 2026)
Protara Therapeutics' (TARA) quarterly Return on Capital Employed came in at 36.53% in Q1 2026, down 592.0% year-on-year from 7.42% in Q1 2025, and up 5.99% on a QoQ basis from 38.86% in Q4 2025.
Protara Therapeutics (TARA) Return on Capital Employed (2014 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has 13 years of Return on Capital Employed data on file, last reported at 36.53% in Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 592.0% year-over-year to 36.53% in Q1 2026; TTM through Mar 2026 was 36.53%, a 592.0% decrease from a year earlier, with the FY2025 full-year figure at 34.98%, up 624.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 36.53%, up from 38.86% in the prior quarter.
- Over the last five years, Return on Capital Employed for TARA reached as high as 25.56% in Q3 2022 and fell as low as 84.77% in Q3 2023.
- Historically, Return on Capital Employed has averaged 47.59% across 5 years, with a median of 42.44% in 2025.
- Across the five-year window, Return on Capital Employed tumbled 5921 bps in 2023 and jumped 3660 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 53.56% in 2022, then declined by 5 bps to 56.23% in 2023, then soared by 31 bps to 38.76% in 2024, then decreased by 0 bps to 38.86% in 2025, then rose by 6 bps to 36.53% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 36.53% in Q1 2026, 38.86% in Q4 2025, and 42.44% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Protara Therapeutics | 2.25 Mn | 2.25 Mn | - | -36.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.53% |
| Dec 31, 2025 | -38.86% |
| Sep 30, 2025 | -42.44% |
| Jun 30, 2025 | -37.49% |
| Mar 31, 2025 | -30.61% |
| Dec 31, 2024 | -38.76% |
| Sep 30, 2024 | -51.42% |
| Jun 30, 2024 | -55.85% |
| Mar 31, 2024 | -67.21% |
| Dec 31, 2023 | -56.23% |
| Sep 30, 2023 | -84.77% |
| Jun 30, 2023 | -72.36% |
| Mar 31, 2023 | -63.73% |
| Dec 31, 2022 | -53.56% |
| Sep 30, 2022 | -25.56% |
| Jun 30, 2022 | -26.33% |
| Mar 31, 2022 | -27.30% |
| Dec 31, 2021 | -27.55% |
| Sep 30, 2021 | -25.49% |
| Jun 30, 2021 | -23.21% |